



## **CURRICULUM VITAE**

**1/2/2024**

Name: **Raúl Méndez**

Date of birth: October 22<sup>th</sup>, 1965

ICREA and Institute for Research in Biomedicine (IRB).

Program of Molecular Medicine.

Group of Translational control of cell cycle and differentiation

Parc Científic de Barcelona.

Baldiri Reixac, 10

08028 Barcelona.

SPAIN

Ph# +34 93 403 1900

Fax# +34 93 403 1902

## **EDUCATIONAL BACKGROUND**

- Graduate Degree (Biology/ Biochemistry). Universidad Autónoma de Madrid, Spain (1982-1988).
- Ph.D. (Biochemistry/ Molecular Biology). Centro de Biología Molecular “Severo Ochoa”, Universidad Autónoma de Madrid, Spain (1988-1993). Advisor: Dr. César de Haro.

## **PROFESSIONAL EXPERIENCE**

- Research Associate. Department of Cytogenetics, Universidad Autonoma de Madrid, Spain (1986-1987).
- Research Associate. Department of Biochemistry and Molecular Biology, Universidad Autonoma de Madrid, Spain (1987-1988).
- Postdoctoral Research Associate. Louisiana State University Medical Center, Shreveport, Louisiana (USA). Advisor: Dr. Robert E. Rhoads (1994-1997).
- Postdoctoral Research Associate. University of Massachusetts Medical Center, Worcester, Massachusetts (USA). Advisor: Dr. Joel Richter (1997-2001).
- Group Leader, Program of Gene Expression, Center for Genomic Regulation (CRG), Barcelona, Spain (2002-2010).
- ICREA professor, Institute of Research in Biomedicine (IRB), Barcelona, Spain. Program of Molecular Medicine (2011-present).
- IRB Vice-Director (2018-present).

## TEACHING EXPERIENCE

- Practical classes “Metodología Bioquímica”, 4<sup>th</sup> year of the Undergraduate Programme. Biological Sciences (Biochemistry). Universidad Autónoma de Madrid (1989-1991).
- Practical classes “Genética Molecular II”, 5<sup>th</sup> year of the Undergraduate Programme. Biological Sciences (Biochemistry). Universidad Autónoma de Madrid (1991-1993).
- 5<sup>th</sup> year of the Undergraduate Programme, Cellular and Molecular Pathology Programme, Department of Health and Experimental Sciences, University Pompeu Fabra, "Frontiers of Molecular Pathology: Basic Mechanisms of Gene Expression and its Regulation" and “Problem Based Learning (PBL)” 2003-2006.
- International PhD Programme Basic Biomedical Research Health and Life Sciences, "Gene Expression and Regulation", Department of Health and Life Sciences, University Pompeu Fabra, 2003-2011.
- Master in Biomedical research (BIOMED), International PhD Programme, Department of Health and Life Sciences, University Pompeu Fabra, 2007-2018.
- Member of the DEA tribunal. International PhD Programme, Department of Health and Life Sciences, University Pompeu Fabra.

## Thesis directed

- **17 PhD. Thesis directed:** Carolina Eliscovich (2008), Eulàlia Belloc (2008), Ana Igea (2009), Alessio Bava (2013), Valeria Giangarra (2013), Vittorio Calderone (2013), Jordina Guillén (2015), Carlos Maillo (2016), Hector Anta (2016), Joan Gibert (2017), Irene Pazos (2018), Rosa Pascual (2018) Clara Suñer (2018), Manuel Cañete (2020), Berta Duran (2020), Marcos Fernandez (2022), Anna Bartomeu (2024).
- **4 Ongoing:** Anna Ferrer (Expected defense 2024), Marina Malumbres (Expected defense 2025), Camilla Bertani (Expected defense 2026) and Elsa Tusquets (Expected defense 2026)

## PUBLICATIONS (h Factor 37, 5742 citations): Scopus Author ID: 7103276536. Orcid ID: Orcid.org/0000-0002-1952-6905

1. E. Méndez, A. Moreno, F. Colilla, F. Pelaez, G. Limas, **R. Méndez**, F. Soriano, M. Salinas, and C. de Haro. "Primary structure and inhibition of protein synthesis in eukaryotic cell-free system of a novel thionin, g-hordothionin, from Barley endosperm". *Eur. J. Biochem.* 194: 533-539 (1990).
2. A. Moreno, **R. Méndez**, and C. de Haro. "Characterization of cell-free protein-synthesis systems from undeveloped and developing *Artemia* embryos". *Biochem J.* 276: 809-816 (1991).
3. **R. Méndez**, A. Moreno, and C. de Haro. "Regulation of heme controlled eukaryotic polipeptide chain initiation factor 2a-subunit kinase of reticulocyte lysates". *J. Biol. Chem.* 267: 11500-11507 (1992).
4. **R. Méndez**, and C. de Haro. "Casein kinase II is implicated in the regulation of heme-controlled translational inhibitor of reticulocyte lysates". *J. Biol. Chem.* 269: 6170-6176 (1994).
5. C. de Haro, **R. Méndez**, and J. Santoyo. "The eIF-2a kinases and the control of protein synthesis". *FASEB J.* 10: 1378-1387 (1996).
6. J. Santoyo, J. Alcalde, **R. Méndez**, D. Pulido, and C. de Haro. "Cloning and characterization of a cDNA encoding a protein synthesis initiation factor-2alpha (eIF-2alpha) kinase from *Drosophila melanogaster*. Homology to yeast gcn2 protein kinase". *J. Biol. Chem.* 272: 12544-12550 (1997).

7. B. Joshi, A. Cai, B.D. Keiper, W.B. Minich, **R. Méndez**, C. Beach, J. Stepinski, R. Stolarski, E. Darzynkiewicz, and R. E. Rhoads. "Phosphorylation of eukaryotic protein synthesis initiation factor 4E at Ser-209". *J. Biol. Chem.* 270: 14597-14603 (1995).
8. **R. Méndez**, M.G. Myers, M.F. White, and R.E. Rhoads. "Stimulation of protein synthesis, eukaryotic translation initiation factor 4E phosphorylation, and PHAS-I phosphorylation by insulin requires insulin receptor substrate 1 and phosphatidylinositol 3-kinase". *Mol. Cell Biol.* 16: 2857-2864 (1996).
9. **R. Méndez**, G. Kollmorgen, M.F. White, and R.E. Rhoads. "Requirement of PKC $\zeta$  for stimulation of protein synthesis by insulin". *Mol. Cell Biol.* 17, 5184-5192 (1997).
10. M. G. Jr. Myers, **R. Méndez**, P. Shi, J. H. Pierce, R. E. Rhoads, and M. F. White. "The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling". *J. Biol. Chem.* 273: 26908-26914 (1998).
11. L. E. Hake, **R. Méndez**, and J. D. Richter. "Specificity of RNA binding by CPEB: Requirement for RNA recognition motifs and a novel zinc finger". *Mol. Cell Biol.* 18: 685-693 (1998).
12. B. Stebbins-Boaz, Q. Cao, C. H. de Moor, **R. Méndez**, and J. D. Richter. "Maskin is a CPEB associated factor that transiently interacts with eIF-4E". *Mol. Cell* 4: 1017-1027 (1999).
13. **R. Méndez**, L. E. Hake, T. Andresson, L. E. Littlepage, J. V. Ruderman and J. D. Richter. "Phosphorylation of CPE binding factor by Eg2 regulates translation of c-mos mRNA". *Nature* 404: 302-307 (2000).
14. **R. Méndez**, K. G. Murthy, K. Ryan, J. L. Manley and J. D. Richter. "Phosphorylation of CPEB by Eg2 mediates the recruitment of CPSF into an active cytoplasmic polyadenylation complex". *Mol. Cell* 6: 1253-1259 (2000).
15. I. Groisman, Y-S. Huang, **R. Méndez**, Q. Cao, W. Theurkauf and J. D. Richter. "CPEB, maskin, and cyclin B1 mRNA at the mitotic apparatus: Implications for local translational control of cell division". *Cell* 103: 435-447 (2000).
16. **R. Méndez**, G. Welsh, M., Kleijn, M. G. Myers, M. F. White, C. G. Proud and R. E. Rhoads. "Regulation of protein synthesis by insulin through IRS-1". In: Signaling Pathways for Translation. Insulin and Nutrients. Editor: R. E. Rhoads. *Progress in Molecular and Subcellular Biology*. Springer-Verlag, Berlin/Heidelberg. Volume 26; 49-94 (2001).
17. R. Hodgman, J. Tay, **R. Méndez** and J. D. Richter. "CPEB phosphorylation and cytoplasmic polyadenylation are catalyzed by the kinase IAK1/Eg2 in maturing mouse oocytes". *Development* 128: 2815-2822 (2001).
18. **R. Méndez** and J. D. Richter. "Translational control by CPEB: A means to the end". *Nat Rev Mol Cell Biol.* 2: 521-529 (2001).
19. **R. Méndez**, Barnard D and J. D. Richter. "Differential mRNA translation and meiotic progression require Cdc2-mediated CPEB destruction." *EMBO J.* 21: 1833-1844 (2002).
20. I. Groisman, YS. Huang, **R. Méndez**, Q. Cao and J.D. Richter. "Translational control of embryonic cell division by CPEB and Maskin". The Ribosome Vol. 66. *Cold Spring Harbor Symposium of Quantitative Biology LXVI*: 345-351 (2002).
21. **R. Méndez**, and D. Wells. "Location, location, location: translational control in development and neurobiology". *Trends in Cell Biol.* 2: 407-409 (2002).
22. M. Sarkissian, **R. Méndez** and J.D. Richter. "Progesterone and insulin stimulation of CPEB-dependent polyadenylation is regulated by Aurora A and glycogen synthase kinase-3". *Genes & Development*, 18: 48-61 (2004).

23. M. Piqué M, J.M. López and **R. Méndez**. “ Cytoplasmic mRNA polyadenylation and translation assays”. *Methods in Molecular Biology*, 322: 183-198 (2006).
24. M. Fernández, M. Mejías, E. García-Pras, **R. Méndez**, J.C. García-Pagán, and J. Bosch. “Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats”. *Hepatology*, 46: 1208-1217 (2007).
25. M. Piqué, J.M. López S. Foissac, R. Guigó and **R. Méndez**. “A combinatorial code for CPE-mediated translational control” *Cell*, 132(3):434-448. (2008).
26. E. Belloc and **R. Méndez**. “A deadenylation negative feedback mechanism governs meiotic metaphase arrest”. *Nature*, 452(7190):1017-21 (2008).
27. C. Eliscovich I. Peset, I. Vernos and **R. Méndez**. “ Spindle Localized CPE-mediated translation controls meiotic chromosome segregation” *Nature Cell Biology*, 10(7):858-865. (2008).
28. E. Belloc, M. Piqué and **R. Méndez**. “Sequential waves of polyadenylation and deadenylation define a translation circuit that drives meiotic progression”. *Biochemical Society Transactions*, 36(Pt 4):665-670, (2008).
29. M. Mejías, E. García-Pras, J. Gallego, **R. Méndez**, J. Bosch and M. Fernández. “Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension”. *Journal of Hepatology*, 52(4):529-539. (2010).
30. Isabel Novoa, Javier Gallego, Pedro G. Ferreira, **Raúl Méndez**. “Mitotic cell cycle progression is regulated by CPEB-dependent translational control” *Nature Cell Biology*. 12(5):447-456. (2010).
31. Isabel Novoa, Carolina Eliscovich, Eulalia Belloc and **Raul Mendez**. “Oocyte-specific translational control mechanisms” Book Chapter. Oogenesis: The Universal Process Marie-Helene Verlhac and Anne Villeneuve, 2010 John Wiley & Sons, Ltd. (2010).
32. Ana Igea and **Raúl Méndez**. "Meiosis requires a translational positive loop where CPEB1 ensues its replacement by CPEB4". *EMBO J*. 29(13):2182-2193. (2010).
33. Ortiz-Zapater, E., Pineda, D., Martínez-Bosch, N., Fernandez-Miranda, G., Iglesias, M., Alameda F., Moreno, M., Eliscovich, C., Eyra, E., Real, F.X., **Méndez, R.\*** and Navarro, P.\*. (\* Equal contribution. Co-corresponding authors). “Key contribution of CPEB4-mediated translational control to cancer progression.” *Nature Medicine*. 18(1):83-90. (2011).
34. Weill L, Belloc E, Bava FA, **Méndez R**. “Translational control by changes in poly(A) tail length: recycling mRNAs.” *Nat Struct Mol Biol*. 19(6):577-85. (2012).
35. Fernández-Miranda G, **Méndez R**. “The CPEB-family of proteins, translational control in senescence and cancer.” *Ageing Res Rev*. 11(4):460-72. (2012).
36. Bava, FA., Eliscovich, C., Ferreira, PG., Miñana, B., Ben-Dov, C., Guigó, R., Valcárcel, J. and **Méndez, R**. “CPEB1 coordinates alternative 3’UTR formation with translational regulation”. *Nature*, 495(7439):121-125 (2013).
37. Marqués N, Sesé M, Cánovas V, Valente F, Bermudo R, de Torres I, Fernández Y, Abasolo I, Fernández PL, Contreras H, Castellón E, Celià-Terrassa T, **Méndez R**, Ramón Y Cajal S, Thomson TM, Paciucci R. “Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1”. *Oncogene*. 33(9):1124-1134 (2014).
38. Coch L, Mejias M, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, **Mendez R**, Fernandez M. "Disruption of negative feedback loop between Vasohibin-1 and VEGF decreases portal pressure, angiogenesis and fibrosis in cirrhotic rats". *Hepatology*. 60(2):633-647. (2014).
39. Tariq Afroz, Lenka Skrisovska, Eulàlia Belloc, Jordina Guillén-Boixet, **Raúl Méndez\*** and Frédéric H.T-Allain\* (\* Co-Corresponding Authors). “A fly trap mechanism provides

- sequence-specific RNA recognition by CPEB proteins". *Genes & Development* 28(13): 1498-1514 (2014).
40. Elena Doménech, Carolina Maestre, Lorena Esteban-Martínez, David Partida, Rosa Pascual, Gonzalo Fernández-Miranda, Ramón Campos-Olivas, Manuel Pérez, Diego Megias, Katherine Allen, Miguel López, Asish K. Saha, Guillermo Velasco, Eduardo Rial, **Raúl Méndez**, Patricia Boya, María Salazar-Roa and Marcos Malumbres "AMPK and PFKFB3 mediate glycolysis and survival during mitotic arrest". *Nature Cell Biology*. 17(10), 1304–1316. (2015).
  41. Giangarrà V, Igea A, Castellazzi CL, Bava FA, **Mendez R**. "Global analysis of CPEBs reveals sequential and non-redundant functions in mitotic cell cycle." *Plos One*. 10(9):e0138794. doi: 10.1371/journal.pone.0138794. (2015).
  42. Calderone V, Gallego J, Fernandez-Miranda G, Garcia-Pras E, Maillo C, Berzigotti A, Mejias M, Bava FA, Navarro P, Bosch J, Fernandez M\*, **Mendez R**.\* "Sequential functions of CPEB1 and CPEB4 regulate VEGF expression and angiogenesis in chronic liver disease". *Gastroenterology*. 150(4): 982-997.e30 (2016).
  43. Garcia-Pras, E., Gallego, J., Coch, L., Mejias, M., Fernandez-Miranda, G., Pardal, R., Bosch, J., **Mendez, R.** and Fernandez, M. "Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension" *Gut* 66(7):1306-1320. (2017).
  44. Maldonado R, Mancilla H, Villarroya-Espíndola F, Slebe F, Slebe JC, **Méndez R**, Guinovart JJ and Concha II. "An inactive muscle glycogen synthase is possibly associated with RNA related molecules in Sertoli cells" *Journal of Cellular Biochemistry* 2597-2607 (2016).
  45. Pérez-Guijarro E, Karras P, Cifdaloz M, Martínez-Herranz R, Cañón E, Graña O, Horcajada-Reales C, Alonso-Curbelo D, Calvo TG, Gómez-López G, Bellora N, Riveiro-Falkenbach E, Ortiz-Romero PL, Rodríguez-Peralto JL, Maestre L, Roncador G, de Agustín Asensio JC, Goding CR, Eyra E, Megias D, **Méndez R** and Soengas MS. "Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers." *Nature Communications*. 7:13418. doi: 10.1038/ncomms13418. (2016).
  46. Guillén-Boixet J, Buzon V, Salvatella X and **Méndez R**. "CPEB4 is regulated during cell cycle by ERK2/Cdk1-mediated phosphorylation and its assembly into liquid-like droplets" *eLife* pii: e19298. doi: 10.7554/eLife.19298. (2016).
  47. Maillo C, Martín J, Sebastián D, Hernández-Alvarez M, García-Rocha M, Reina O, Zorzano A, Fernandez M, and **Méndez R**. "Circadian and UPR-dependent control of CPEB4 mediates a translational response to counteract hepatic steatosis under ER stress" *Nature Cell Biology*. 19, 94–105 (2017).
  48. Villanueva E, Navarro P, Rovira-Rigau M, Sibilio A, **Méndez R\***, and Fillat C.\* (\* Co-Corresponding Authors). Translational reprogramming in tumor cells can generate oncoselectivity in viral therapies". *Nature Communications* 8:14833. doi:10.1038/ncomms14833. (2017).
  49. Weill L, Belloc E, Castellazzi C.L and **Méndez R**. "Musashi 1 regulates the timing and extent of meiotic mRNA translational activation by promoting the use of specific CPEs." *Nat Struct Mol Biol*. 24(8):672-681 (2017).
  50. Lou WP, Mateos A, Koch M, Klussman S, Yang C, Lu N, Kumar S, Limpert S, Göpferich M, Zschaetzsch M, Sliwinski C, Kenzelmann M, Seedorf M, Maillo C, Senis E, Grimm D, Puttagunta R, **Mendez R**, Liu K, Hassan BA, Martín-Villalba A "Regulation of adult CNS axonal regeneration by the post-transcriptional regulator Cpeb1" *Front. Mol. Neurosci*. 10:445. doi: 10.3389/fnmol.2017.00445. (2018).
  51. Parras A, Anta H, Santos-Galindo M, Swarup V, Elorza A, Nieto-González JL, Picó S, Hernández IH, Díaz-Hernández JI, Belloc E, Rodolosse A, Parikshak NN, Peñagarikano O,

- Fernández-Chacón R, Irimia M, Navarro P, Geschwind DH, **Méndez R\***, Lucas JJ\*. (*\* co-corresponding authors*). “Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing.” *Nature*. 560(7719):441-446. (2018).
52. Pascual R, Martín J, Salvador F, Reina O, Chanes V, Millanes-Romero A, Suñer C, Fernández-Miranda G, Bartomeu A, Huang YS, Gomis RR, and **Méndez R**. “The RNA-binding protein CPEB2 regulates hormone sensing in mammary gland development and breast cancer” *Science Advances* 6(20):eaax3868 (2020).
  53. Mejias M, Gallego J, Naranjo-Suarez S, Ramirez M, Pell N, Manzano A, Suñer C, Bartrons R, **Mendez R**, and Fernandez M. “CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis” *Gastroenterology* 159(1):273-288. (2020).
  54. Parras A, de Diego-Garcia L, Alves M, Beamer E, Conte G, Jimenez-Mateos EM, Morgan J, Ollà I, Hernandez-Santana Y, Delanty N, Farrell MA, O'Brien DF, Ocampo A, Henshall DC, **Méndez R**, Lucas JJ, Engel T. “Polyadenylation of mRNA as a novel regulatory mechanism of gene expression in temporal lobe epilepsy”. *Brain*. pii: awaa168. doi: 10.1093/brain/awaa168 (2020).
  55. Conte G, Parras A, Alves M, Ollà I, De Diego-Garcia L, Beamer E, Alalqam R, Ocampo A, Mendez R, Henshall DC, Lucas JJ, Engel T. “High concordance between hippocampal transcriptome of the mouse intraamygdala kainic acid model and human temporal lobe epilepsy” *Epilepsia* 2020;61:2795–2810. (2020).
  56. Pascual R, Segura-Morales C, Omerzu M, Bellora N, Belloc E, Castellazzi CL, Reina O, Eyraas E, Maurice MM, Millanes-Romero A, and **Méndez R**. “mRNA spindle localization and mitotic translational regulation by CPEB1 and CPEB4” *RNA* 27(3):291-302 (2020).
  57. Riechert E, Kmietczyk V, Stein F, Schwarzl T, Sekaran T, Jürgensen L, Kamuf-Schenk V, Varma E, Hofmann C, Rettel M, Gür K, Ölschläger J, Kühl F, Martin J, Ramirez-Pedraza M, Fernandez M, Doroudgar S, **Méndez R**, Katus HA, Hentze MW, Völkers M. “Identification of dynamic RNA-binding proteins uncovers a Cpeb4-controlled regulatory cascade during pathological cell growth of cardiomyocytes” *Cell Reports* 35(6):109100 (2021).
  58. Picó S, Parras A, Santos-Galindo M, Pose-Utrilla J, Castro M, Fraga E, Hernández IH, Elorza A, Anta H, Wang N, Martí-Sánchez L, Belloc E, Garcia-Esparcia P, Garrido JJ, Ferrer I, Macías-García D, Mir P, Artuch R, Pérez B, Hernández F, Navarro P, López-Sendón JL, Iglesias T, Yang XW, **Méndez R**, and Lucas JJ. “CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease” *Sci Transl Med*. 29;13(613):eabe7104. (2021).
  59. Pell N, Garcia-Pras E, Gallego J, Naranjo-Suarez S, Balvey A, Suñer C, Fernandez-Alfara M, Chanes V, Carbo J, Ramirez-Pedraza M, Reina O, Thingholm L, Bang C, Rühlemann M, Franke A, Schierwagen R, Rheinwald KP, Trebicka J, **Mendez R**, and Fernandez M. “Targeting the cytoplasmic polyadenylation element binding protein CPEB4 protects against diet-induced obesity and microbiome dysbiosis.” *Mol Metab*. doi: 10.1016/j.molmet.2021.101388. (2021).
  60. Sibilio A, Suñer C, Fernández-Alfara M, Martín J, Berenguer A, Calon A, Chanes V, Millanes-Romero A, Fernández-Miranda G, Batlle E, Fernández M, and **Méndez R**. “Immune translational control by CPEB4 regulates intestinal inflammation resolution and colorectal cancer development” *iScience* 25(2):103790. (2022).
  61. Suñer C, Sibilio A, Martín J, Castellazzi CL, Reina O, Dotu I, Caballé A, Rivas E, Calderone V, Díez J, Nebreda AR, Méndez R. “Macrophage inflammation resolution requires CPEB4-directed offsetting of mRNA degradation” *eLife* (2022). doi: 10.7554/eLife.75873.
  62. Duran-Arqué B, Cañete M, Castellazzi CL, Bartomeu A, Ferrer-Caelles A, Reina O, Caballé A, Gay M, Arauz-Garofalo G, Belloc E, and **Mendez R**. “Comparative analyses of

vertebrate CPEB proteins define two subfamilies with coordinated yet distinct functions in post-transcriptional gene regulation” *Genome Biology* 23(1):192 (2022).

63. Fernández-Alfara M, Sibilio A, Martin J, Tusquets Uxó E, Malumbres M, Alcalde V, Chanes V, Cañellas-Socias A, Palomo-Ponce S, Batlle E, and **Méndez R**. “Antitumor T cell function requires CPEB4-mediated adaptation to chronic endoplasmic reticulum stress” *EMBO Journal* 42(9):e111494 (2023).
64. Huang, Y.S.<sup>\*#</sup>, **Mendez, R.**<sup>\*#</sup>, Fernandez M.<sup>4</sup> and Richter J.D.<sup>#</sup> (*\*equal contributors* *#corresponding authors*) “CPEB and Translational Control by Cytoplasmic Polyadenylation: Impact on Synaptic Plasticity, Learning, and Memory” *Molecular Psychiatry* 28(7):2728-2736 (2023).
65. Ollà I, Pardiñas AF, Parras A, Hernández IH, Santos-Galindo M, Picó S, Callado LF, Elorza A, Rodríguez-López C, Fernández-Miranda G, Belloc E, Walters JTR, O'Donovan MC, Méndez R, Toma C, Meana JJ, Owen MJ, Lucas JJ. “Pathogenic mis-splicing of *CPEB4* in schizophrenia” *Biological Psychiatry* S0006-3223(23)01161-7. (2023).
66. Cobo I, Paliwal S, Bodas C, Felipe I, Melià-Alomà J, Torres A, Martínez-Villarreal J, Malumbres M, García F, Millán I, Del Pozo N, Park JC, MacDonald RJ, Muñoz J, **Méndez R**, and Real FX “NFIC regulates ribosomal biology and ER stress in pancreatic acinar cells and suppresses PDAC initiation” *Nat. Comm.* 14(1):3761.doi: 10.1038/s41467-023-39291-x. (2023).
67. de Diego-García L, Brennan GP, Auer T, Menendez-Mendez A, Parras A, Martín-Gil A, Mitra M, Ollà I, Villalba-Benito L, Gil B, Alves M, Lau K, Delanty N, Beausang A, Cryan J, Brett FM, Farrell MA, O'Brien DF, **Mendez R**, Carracedo-Rodríguez G, Henshall DC, Lucas JJ, Engel T “CPEB4 - CLOCK crosstalk during temporal lobe epilepsy” *Epilepsia* 64(10):2827-2840 (2023).

### **Under Review and Submitted:**

1. Manuel Göpferich, Nikhil Oommen George, Ana omingo Muelas, Alex Bizyn, Rosa Pascual, DariaFijalkowska, Georgios Kalamakis, Ulrike Müller, Jeroen Krijgsveld, **Raul Mendez**, Isabel Fariñas, WolfgangHuber, Simon Anders, Ana Martín-Villalba “Single cell 3’UTR analysis identifies changes in alternative polyadenylation throughout neuronal differentiation and in autism” [bioRxiv 2020.08.12.247627](https://doi.org/10.1101/2020.08.12.247627); doi: <https://doi.org/10.1101/2020.08.12.247627>
2. Carla Garcia-Cabau<sup>#</sup>, Anna Bartomeu<sup>#</sup>, Andreea Balaceanu, Giulio Tesei, Berta Duran-Arqué, Marcos Fernández-Alfara, Judit Martín, Cesare De Pace, Lorena Ruiz-Pérez, Jesús García, Giuseppe Battaglia, Kresten Lindorff-Larsen, **Raúl Méndez**<sup>\*\*</sup>, Xavier Salvatella<sup>\*\*</sup> (*\* co-corresponding authors*). “Kinetic stabilization of translation repression condensates by a neuron-specific microexon”. *Second round of review Nature* <https://www.biorxiv.org/content/10.1101/2023.03.19.532587v1>

### **PATENTS**

1. “Peptides blocking kinase and translational activity”. J. D. Richter and **R. Méndez**. UMMC 99-43
2. “Método para el diagnóstico o pronóstico del cáncer de páncreas”. Elena Ortiz-Zapater, Francisco X. Real, Pilar Navarro and **Raúl Méndez**. Application number (P 201130819).

3. Nucleic acid constructs and vectors for oncoselective expression of a transgene (N/Ref.: P12889EP00) Eneko Villanueva, Cristina Fillat, Raúl Méndez

### **FINANCIAL SUPPORT**

- 1- Financing agency: Ministerio de Ciencia y Tecnología (Programa Ramón y Cajal). Date: 2001-2006. Amount: 157,907.81 € (Salary) + 6000 € (consumables). P.I.: Raúl Méndez.
- 2- Financing agency: DURSI (2002SGR00123). Date: 2002-2004. Amount: 33,711 €. P.I.: Miguel Beato del Rosal.
- 3- Financing agency: Ministerio de Ciencia y Tecnología. (SAF2002-03201). Date: 2002-2005. Amount: 162,400 €. P.I.: Raúl Méndez.
- 4- Financing agency: Fundació Marató TV3 (030631). Date: 2004-2006. Amount: 120,584.27 €. P.I.: Raúl Méndez.
- 5- Financing agency: Fundació La Caixa. Date: 2003-2006. Amount: 120,000 €. P.I.: Raúl Méndez.
- 6- Financing agency: DURSI (2005sgr00035). Date: 2005-2008. Amount: 26,600 €. P.I.: Raúl Méndez.
- 7- Financing agency: Ministerio de Educación y Ciencia (BFU2005-05203). Date: 2005-2008. Amount: 154,700 €. P.I.: Raúl Méndez.
- 8- Financing agency: Fundació Marató TV3 (051110). Date: 2006-2009. Amount: 244,668 €. P.I.: Pilar Navarro (IMIM)/ Co-P.I.: Raúl Méndez (CRG).
- 9- Financing agency: Ministerio de Ciencia y Tecnología (Programa I3). Date: 2006-2009. Amount: 129,999.99 €. (Salary). P.I.: Raúl Méndez.
- 10- Financing agency: Ministerio de Ciencia y Tecnología (BFU2008-02373). Date: 2009-2011. Amount: 320,000 €. P.I.: Raúl Méndez.
- 11- Financing agency: AGAUR (SGR 2009-2013). Date: 2009-2013. Amount: 43.680 €. P.I.: Raúl Méndez.
- 12- Financing agency: Ministerio de Ciencia e Innovación. (CSD2009-00080). Date: 2010-2014. Amount 391,666 €. P.I.: Raúl Méndez.
- 13- Association for International Cancer Research (AICR11-0086). 2011-2013. 112,393 £-. P.I.: Raúl Méndez.
- 14- Financing agency: Ministerio de Ciencia y Tecnología (BFU2011-30121). Date: 2012-2014. Amount: 480,000 €. P.I.: Raúl Méndez.
- 15- Financing agency: AGAUR (2014 SGR 127). Date 01/01/2014- 31/12/2016. Amount: 21,000 €. P.I.: Raúl Méndez.
- 16- Financing agency: Fundación Marcelino Botín. Date 01/01/2014- 31/12/2018. Amount: 625,000 €. P.I.: Raúl Méndez.
- 17- Financing agency: Ministerio de Economía (BFU2014-54122-P). Date 01/01/2015- 31/12/2017. Amount: 600,000 €. P.I.: Raúl Méndez.
- 18- Financing agency: AECC (Grupos Estables Coordinados). Amount total: 1,200,000 €. P.I.: Raúl Méndez (coordinator). 551.780€ to R.M group



- 19- Financing agency: WCRF International Regular Grant Programme. Date 01/01/2016-31/12/2018 Amount:250,000 € P.I.: Raúl Méndez (coPI Mercedes Fernandez IDIBAPS)
- 20- Financing agency: Ministerio de Economía (BFU2017-83561-P). Date 01/01/2018-31/12/2020. Amount: 450,000 €. P.I.: Raúl Méndez.
- 21- Financing agency: AGAUR (2017 SGR 1451). Date 01/01/2017- 31/12/2020. Amount: 41,950 €. P.I.: Raúl Méndez.
- 22- Financing agency: “WWCR Foundation Title: “Targeting CPEB-mediated translational balance.” Date 01/1/2020- 31/12/2022. Amount: 217,020 £. P.I.: Raúl Méndez.
23. Financing agency: “la Caixa” Foundation Title: “Post-transcriptional gene regulation reprogramming in obesity-driven liver cancer.” Date 01/10/2019- 01/10/2021. Amount: 500,000 €. P.I.: Raúl Méndez.
24. Financing agency: Fundacion BBVA. Title: “Metabolic reprogramming in liver cancer” Date 01/05/2019- 01/05/2021. Amount: 124.993 €. P.I.: Raúl Méndez.
25. Financing agency: Marato TV3. Title: “Reprogramació metabòlica del càncer de fetge basat en l'obesitat: mecanismes, funcions i oportunitats terapèutiques.” Date 01/01/2020-31/12/2022. Amount: 300,000 €. P.I.: Raúl Méndez.
26. Financing agency: World Cancer Research Fund International. IG\_FULL\_2020\_021. Title: “Identifying New Therapeutic Targets in Obesity-Driven Liver Cancer.” Date 01/01/2021-31/12/2024. Amount: £349,962.00 (385,213.67 €). P.I.: Raúl Méndez.
27. Financing agency: Ministerio de ciencia e innovación PDC2021-121716-I00. Title: “desarrollo de inhibidores de cpeb con propiedades antitumorales.” Date 01/01/2022-31/12/2023. Amount: 156.554,00 €. P.I.: Raúl Méndez.
28. Financing agency: Ministerio de ciencia e innovación PID2020-119533GB-I00. Title: “control traduccional mediado por cpebs en la interaccion tumor-nicho: una perspectiva mecanistica.” Date 01/01/2021- 31/12/2023. Amount: 453.750,00 €. P.I.: Raúl Méndez.
29. Financing agency: AECC (Grupos Estables Coordinados). Title: Targeting circadian epigenetic and posttranscriptional reprogramming of gene expression in liver cancer caused by obesity and aging, a transgenerational perspective Date 01/01/2024- 31/12/2028.Amount Total: 1,200,000 € (400.000€ to R.M). P.I.: Raúl Méndez (Coordinator: Salvador Aznar-Benitah).

#### **INVITED CONFERENCES (Selected)**

- EMBL, Heidelberg, (2002)
- Institut d'Investigacions Biomèdiques de Barcelona (IIBB-CSIC). Barcelona, Spain (2002).
- University of Cambridge. Cambridge, United Kingdom (2003).
- Centre for Biochemistry and Cell Biology, Queen's Medical Centre, University of Nottingham. Nottingham, United Kingdom (2003).
- Centro de Investigación del Cancer, Universidad de Salamanca, CSIC. Salamanca, Spain (2004).
- Workshop “Gene Expression and Cellular Responses”, IBMC/ GABBA. Porto, Portugal (2004).
- Workshop “Animal Models for Cancer”, Institut Municipal d'Investigacions Mèdiques (IMIM). Barcelona, Spain (2004).
- CNRS, Univ PM Curie, Villefranche sur Mer, France (2005).

- EMBO/CSHL conference. “protein Synthesis and translational control” Session Chair (2005)
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona. Barcelona, Spain (2006).
- Universidad Autonoma de Barcelona. Barcelona, Spain (2007).
- Instituto de Parasitología y Biomedicina "López Neyra". Granada, Spain (2007).
- Gene expression and analysis meeting, Biochemical Society Transactions , University of Manchester, UK (2008).
- XII congreso nacional ASEICA (2009).
- workshop "RNA-protein interactions in development and cancer", Baeza, Spain; (October 2009).
- XIII Congreso de la Sociedad Española de Biología Celular. Murcia, Spain (December 2009).
- EMBL Conference: The complex life of mRNA: From synthesis to decay. Heidelberg, Germany. (March 2010).
- Research Institute of Molecular Pathology (I.M.P.), Vienna, Austria. (2010)
- Department Genetics and Development, Institut de Genetique Humaine. Montpellier, France (2010).
- 16th European Testis Workshop, Elba, Italy (2010).
- Interfaculty Institute for Biochemistry, Tuebingen, Germany(nov-2010)
- Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland (nov-2010)
- Institut fur Molekularbiologie und Biophysik ETH Zurich. (June 2011)
- The 3<sup>rd</sup> EMBO Meeting, Vienna, (September 2011), Session Chair.
- “Severo Ochoa conference” at the Sociedad de Bioquímica y Biología Molecular de Chile meeting. Valdivia, Chile (September 2011).
- CAVIMER, Sevilla, November 20011. “Nuclear and cytoplasmic regulation of gene expression by the CPEB-family of RNA-binding proteins. From cell cycle to tumor development.”
- Instituto de Recerca del Hospital Universitario Vall d'Hebron 20 Dec 2011.
- ”Posttranscriptional control of gene expression: Mechanisms and role in pathogenesis” March 14 2012 Halle Germany,
- 3rd Annual Conference of the Institut de Medicina Predictiva i Personalitzada del Cancer (IMPPC): RNA Biology in cancer and other diseases. Jointly organized with the Consolider RNAREG Consortium. Barcelona, Spain (May 3-4, 2012).
- Meeting IUBMB\_FEBS sevilla 2012. A new function for CPEB1 coordinates alternative 3’ UTR processing with translational regulation in cell cycle and cancer.
- “mRNA fate workshop”Life and Death of the mRNA in the cytoplasm  
May 23-26, 2012 Riva del Garda Italy
- IMPPC- 11 Junio 2012.
- CRG X anniversary. October 2012
- Centro de Investigación del Cáncer de Salamanca 16 de Mayo de 2013.
- Workshop UNIA “GENE EXPRESSION AS A CIRCULAR PROCESS: CROSS-TALK BETWEEN TRANSCRIPTION” “A new function for CPEB1 coordinates alternative 3’ UTR processing with translational regulation in cell cycle and cancer “Baeza, Spain 3-6 November 2013.
- EMBO Members meeting. “CPEB family of RNA binding proteins” 23-25 October 2013.
- EMBO Workshop: RNA 3’ Ends: mechanism and biological Function in Eukaryotic Genomes. . 25-29 September 2013
- XXXVI Congreso de la SEBBM. “CPEB-mediated regulation of gene expression”. 3-6 September 2013.

- EMBO Conference: Eukaryotic RNA Turnover: From structural Insights to diseases. “A new function for CPEB1 coordinates alternative 3’ UTR processing with translational regulation in cell cycle and cancer.” Strasbourg, France 21-24 April 2013.
- Frontiers in cancer research and therapy. Nobel Forum, Karolinska Institutet, Stockholm. 6-7 March 2014.
- DKFZ-ZMBH Alliance Colloquium Heidelberg 16 May 2014
- Simposio Internacional Fundación Ramón Areces : "Encuentros en la traducción: explorando el papel de la síntesis de proteínas en el estrés y en la enfermedad" Madrid 16-17 June 2014.
- 6th RNA Club Workshop. Bordeaux June 26-27 2014.
- Escuela de Biología Molecular Eladio Viñuela de la UIMP: Retos en Biomedicina molecular en la segunda década del siglo XXI. Reprogramación traduccional de la expresión génica en embriones y tumores 21-25 July 2014.
- IBBTEC Santander, Spain. 3 Sept 2015.
- EMBO Conference: Protein Synthesis and Translational Control. EMBL, Heidelberg. Keynote Speaker. The CPEB-family of RNA-binding proteins, mechanisms of action and new somatic functions. 9-14 Sept 2015 Key Note Speaker.
- Institut de Biomedicina de València – CSIC, Valencia Spain 17/2/2016
- The Novo Nordisk Foundation Center for Protein Research University of Copenhagen, Copenhagen, Denmark 4/3/2016
- 2nd course on Post-Transcriptional Gene Regulation. Institut Curie, Orsay, France 8/3/2016
- Centro de Investigaciones Biológicas (CIB/CSIC), Madrid, Spain 11/3/2016
- International Institute of Molecular and Cell Biology, Warsaw, PI June 9<sup>th</sup>, 2016
- Centre for research in agricultural genomics (crag), Barcelona, Spain 20-05-2016
- Integrated Program in Biochemistry Madison, WI 53706 The CPEB-family of RNA-binding proteins, mechanisms of action and new functions in cell cycle and cancer 12 Sep, 2016
- RNA MaxiGroup Madison WI . 13 Sept 2016
- B-Debate Beyond Cancer Genomics (Organizer) RNA-binding proteins in cancer. Barcelona 13 Oct 2016.
- Instituto de Biomedicina de Sevilla. 12/22/2016. “The CPEB-family of RNA-binding proteins, mechanisms of action and new functions in cell cycle and cancer”
- Gordon Research Conference: Translation Machinery in Health & Disease. Galveston TX United States, 03/19/2017 - 03/24/2017. . “The CPEB-family of RNA-binding proteins, mechanisms of action and new functions in cell cycle and cancer”
- EMBO Workshop on Metabolic disorders and liver cancer. “Circadian- and UPR-dependent control of CPEB4 mediates a translational response to counteract hepatic steatosis under ER stress” April 23-26 2017.
- Cellular organelle dysfunction at the origin of metabolic diseases (3<sup>rd</sup> MetNet International Meeting), “Translational control of ER stress and hepatic lipid metabolism “ May 10<sup>th</sup> 2017
- QBM Lecture Series (Ludwig-Maximilians-University Munich, Germany) “The CPEB family of RNA-binding proteins: Post-transcriptional (re)programming gene expression in homeostasis and disease.” May 15<sup>th</sup> 2017
- Joint Congress SEG+SEBC+SEBD 2017, “The CPEB-family of RNA-binding proteins, mechanisms of action and new functions in cell cycle and cancer” 24 – 27 October 2017.
- CNIO Distinguished Seminars Series “The CPEB family of RNA-binding proteins: Post-transcriptional (re)programming gene expression in homeostasis and disease.” February the 2<sup>nd</sup> 2018
- Cologne Spring Meeting 2018. 7-9 March 2018 “The CPEB-family of RNA-binding proteins, mechanisms of action and new functions in cell cycle and cancer”

- Hubrecht Institute UMC Utrecht “The CPEB-family of RNA-binding proteins, mechanisms of action and new functions in cell cycle and cancer” October 18<sup>th</sup> 2018
- Mini symposium “The epidemic of fatty liver diseases: risk factors, treatment and extrahepatic consequences”. keynote speaker. “Circadian- and UPR-dependent control of CPEB4 mediates a translational response to counteract hepatic steatosis under ER stress” Jerusalem on November 21<sup>st</sup>, 2018.
- Karolinska Institutet (KI) 13 Dec 2018 “The CPEB-family of RNA-binding proteins, mechanisms of action and new functions in cell cycle and cancer”
- Translation machinery and Cancer - May 20-22 2019, Montpellier
- EMBO Workshop ‘RNP network dynamics in development and disease’ 28 September- 2 October 2019 Ljubljana Slovenia
- Lady Davis Institute for Medical Research October 29, 2019 Montreal, Canada
- Virtual EMBO | EMBL Symposium: The Complex Life of RNA 7-10 October 2020
- Translational Control and Microenvironment in Cancer, The 37th Barcelona Biomed Conference 17-21 October 2022 **Organizer** A CPEB4-mediated response to chronic endoplasmic reticulum stress is required for the antitumor effector function of CD8 T lymphocytes
  - AACR Annual Meeting Apr. 2023. Orlando, FL. USA THE CPEB family of RNA binding proteins in the translational control of tumor-niche chronic stress response.

### **HONORS AND AWARDS**

- Research Fellowship from the Universidad Autónoma de Madrid/ Caja de Ahorros de Madrid, Spain (1986-1988).
- Research Fellowship from the Formación de Personal Investigador, Comunidad Autónoma de Madrid, Spain (1989-1993).
- Postdoctoral Research Fellowship from the Formación de Personal Investigador, Ministerio de Educación y Ciencia, Spain (1994-1995).
- Leukemia Society of America Special Fellow Award (1998-2001).
- Honorary Member of the Department of Biochemistry and Molecular Biology de Louisiana State University Medical School (1997).
- Ministerio de Ciencia y Tecnología (Program Ramón y Cajal). (2001-2006)
- Ministerio de Ciencia y Tecnología (Program I3). (2006-2009).
- Nominated *Singular Research Group* by the Department of Universities of the Catalanian Government (DURSI).
- Award “Premio Ciudad de Barcelona” for research (2008).
- “ICREA professor” en la “ICREA Senior Call 2010”.
- Premio Carmen y Severo Ochoa de investigación en Biología Molecular, 2010.
  - EMBO Member 2012

### **OTHER COMMUNITY ACTIVITIES**

- Member of the Ethics Committee of Clinical Research (CEIC) (CRG/UPF/IMIM) (2004-2006).
- Member of the CRG Space and equipment Committee, (2001-2006).
- Member of the review board for the Deutsche Forschungsgemeinschaft (DFG), research unit “Cytoplasmic regulation of gene expression ” (2007).

- Member of the review board for the Deutsche Forschungsgemeinschaft (DFG), Priority Programme “"Deciphering the mRNP code" 2015-2016. And Review Meeting DFG Priority Program 1935 "mRNP code" 2019-2020
- Member of nine thesis committees in the CRG and 7 at the IRB.
- Reviewer for the following agencies and journals:
  - *Agencies*: Agencia Nacional de Evaluación y Prospectiva (ANEP, Spain), FONCyT (Argentina), ANR, (France). “Fondation pour la Recherche Médicale”. 2013 *Fundação para a Ciência e a Tecnologia, I. P.* (FCT)
  - ANR- Programmes Blanc & JCJC SVSE 6, France 2011
  - *Journal*: Molecular and Cellular Biology, Biol. Cell, EMBO Journal, Development, Plos Biology, RNA, Developmental Biology, Genes & Development and Molecular Reproduction and Development.
- The University of Trento peer-review of the International Doctoral School in Biomolecular Sciences (60500020).
- Head PhD. Program IRB, From 2012
- Member IRB Internal Scientific Committee (ISC), From 2012
- Editorial board Translation journal. From 2012
- ANEP (National agency of evaluation and prospective) coordinator of BFS (Basic and systems biology) evaluation panel. 2012-2015.
- Member of the “Comité de admisiones de la SEBBM” (2011-2014)
- Editorial board Cell Stress journal from 2017.
- IRB Vice-Director from 2018.